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This short review describes the localization of somatostatin receptors
with in vitro receptor autoradiography techniques in several non-classi-
cal, normal human somatostat n target tissues as well as in selected
human tumors. In addition to brain, gut and neuroendocrine localiza-
tions, somatostatin receptors are expressed in most lymphatic tissues,
including gut-associated lymphatic tissue, spleen and thymus; in the
cortical and medullary area of the kidney; in the stroma of the prostate
and in the epithelial cells of the thyroid. Among human tumors, the
extremely high density of somatostatin receptors in medulloblastomas
should be stressed as well as the favorable prognostic role of the pres-
ence of somatostatin receptors in neuroblastomas. Moreover, several
types ofmesenchymal tumors have somatostatin receptors as well. The
receptor subtypes expressed by distinct tumors may vary: Whereas
medulloblastomas and neuroblastomas predominantly express sst2,
prostate cancers express sstl rather than sst2. A further emerging
somatostatin target is represented by the peritumoral veins, also known
to express sst2 receptors. The multiple somatostatin targets in normal
and pathological human tissues represents the basis for potential diag-
nostic and clinical applications of somatostatin analogs.
INTRODUCTION
In the last decade, somatostatin receptors (SSt)b were identified in a multitude of nor-
mal human tissues as well as in several types of human tumors. These data have been
reviewed in detail elsewhere [1, 2]. In this article, we would like to focus on a number of
recent data regarding sst distribution in a few selected normal and diseased human tissues.
SST IN NORMAL HUMAN TISSUES
Lymphatic tissue
In addition to the nervous system, endocrine system and gastrointestinal tract, the
human lymphatic tissue represents one ofthe important sites ofsstexpression in the human
body, as observed with in vitro receptor autoradiography. As seen in Table 1, several lym-
phatic organs can express sst: in the gut-associated lymphatic tissue (GALT), all lymphoid
follicles containing germinal centers can be shown to express sst, which are preferentially
a To whom all correspondence should be addressed: J.C. Reubi, M.D., Professor of Pathology,
Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of
Beme, Murtenstrasse 31, CH-3010 Berne, Switzerland. Tel.: 31-632-32-42; Fax: 31-632-89-99 or
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bAbbreviations: sst, somatostatin receptors; GALT, gut-associated lymphatic tissue; GEP, gastroen-
teropancreatic.
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Table 1. Localization ofsst in human lymphatic tissue.
Tissues Site
Lymph nodes Germinal centers
Tonsils Germinal centers
Peyer's patches Germinal centers
Solitary follicles (colon) Germinal centers
Appendix Germinal centers
Spleen Red pulp
Thymus Medulla
A sst subtype evaluation ofthese tissues is not yet available; however, the excellent labeling ofthese
sites by 1 I-[Tyr3]-octreotide [4] indicates a strong expression of sst2.
located in the germinal centers, consisting primarily of activated lymphocytes [3].
Moreover, the red pulpa ofthe spleen is a further site ofsst expression. Finally, the thymus
also appears to be a site of sst expression. All samples from normal thymus in young chil-
dren and adult individuals contained sstlocated in the thymic medulla. Because the medul-
la appears diffusely and homogeneously labeled and because the autoradiographic tech-
nique does not allow assigning the label to a given cell, we do not know whether sst are
located on epithelial cells, stroma, reticulo-endothelial cells or on lymphocytes. No signif-
icant labeling was observed in the cortex norin Hassal's corpuscles [4]. The majority ofthe
sst in the lymphatic organs probably belong to the sst2 subtype, as they can bind octreotide
with high affinity. However, a precise analysis ofthe sst subtypes expressed by lymphatic
tissues is not yet available. The role of somatostatin in human lymphatic tissues has not
been clearly established either.
Kidney
Specific and high affinity sst have been identified in the human kidney. Microscopic
localization of these receptors was revealed by radioligand binding over cortical and
medullary areas. In the cortex, the receptors were located in the proximal tubules [5]. In
the medulla, sst were identified primarily in high density in medullary vasa recta (Figure
1). These sst probably belong to the sst2 subtype since they bind octreotide with high
affinity. The distribution and density of sst in various regions of the renal cortex and
medulla imply that somatostatin has multiple and possibly important functions in the
human kidney. It is difficult, however, to evaluate the extent to which the localization of
sst in various functional units, including vasa recta and proximal tubules, is compatible
with the results of in vivo studies reporting the effects of pharmacological doses of
somatostatin on kidney functions [6]. More studies investigating the physiology and
pathophysiology of somatostatin in the human kidney are needed to understand its role in
this organ and topredict whether the use ofsomatostatin analogs may be ofpotential inter-
est in selected renal diseases.
Prostate
The human prostate expresses sst [7]. Unexpectedly, in all normal and hyperplastic
prostates, the smooth muscles ofthe stroma, but not the glands, were shown to express the
receptors (Figure 2). Muscular nodules were strongly receptor-positive as well. The recep-
tors were ofhigh affinity and high specificity for biologically active somatostatin analogs;
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Figure 1. sst in the vasa recta ofthe medulla
of a human kidney. Sections (A, stained with
hematoxylin-eosin; Bar = 1 mm) were incubat-
ed with '251-[Tyr3]-octreotide and photoemul-
sion-coated to visualize sst in the vasa recta
under dark-field illumination (B). C represents
a detail of a group of vasa recta located in the
black rectangle in A (Bar = 0.1 mm).
Figure 2. sst in a human prostate. A) F-VIII-
like immunoreactivity showing strong labeling
of prostatic glands and vessels (arrowheads).
B) Hematoxylin-eosin stained section showing
the glandular part surrounded by smooth mus-
cle stroma. Bar = 1 mm. C) Autoradiogram
showing total binding of1251-[Tyr3]-octreotide.
Smooth muscles, but not glands, are labeled.
D) Autoradiogram showing non-specific bind-
ing of1251-[Iyr3]-octreotide (in the presence of
10-6 molIl unlabeled octreotide).
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a high affinity for somatostatin-14, somatostatin-28 and octreotide was detected, suggest-
ing the presence of the sst2 receptor subtype. In situ hybridization studies confirmed the
presence of sst2 messenger ribonucleic acid in these tissues [7]. The presence of sst in
prostate stromal cells was confirmed with other methods by Tatoud et al. [8].
No information regarding the precise role and function of sst in the prostate smooth
muscle is presently available. Two sets of data suggest that the identified receptors may
exist in relation with somatostatinergic neuronal input to the prostatic smooth muscle.
First, the peripheral vegetative nervous system, in particular sympathetic efferents, is
known to be somatostatinergic in various parts ofthe body. Second, the nervous prostatic
plexus itself is rich in sst and, therefore, mediates somatostatin action. A somatostatiner-
gic pathway to the prostatic smooth muscle may influence the contractility of the gland,
independently ofthe indirect somatostatin action on the prostate mediatedby thepituitary.
Anotherpossible role of sst in the prostatic stromacould be to influence the release ofvar-
ious growth factors synthesized in the stroma. As several of these growth factors act in a
paracrine manner on the glandularpart ofthe prostate to regulate prostate growth, somato-
statin could indirectly regulate biological events in the prostatic gland through a stromal
action.
Thyroid gland
We have recent data, using in vitro sst autoradiography, showing that surgically
resected goiters ofthe human thyroid gland express sst. In all 15 goiters tested, we found
sst having high affinity for octreotide and being located homogeneously in all epithelial
cells [9]. Since most goiters consist of hyperplastic thyroid tissue, it is likely that similar
receptor characteristics can be expected for the normal thyroid. The observed scinti-
graphic signal with Octreoscan in the normal thyroid, but also in the thyroid in Grave's
disease [10], is likely to be due to sst localized on thyroid epithelial cells.
SST IN NEOPLASTIC TISSUES
General
A wide variety of human tumors express sst, which can be measured in vitro with
radioligand binding techniques using 1251-labeled somatostatin analogs in tumor
homogenates or on tumor sections [1]. One of the tumor groups identified as having the
highest incidence of sst are the neuroendocrine tumors, such as GH- and TSH-producing
pituitary adenomas, non-secreting adenomas, as well as endocrine gastroenteropancreatic
(GEP) tumors, pheochromocytomas, paragangliomas, medullary thyroid carcinomas and
small-cell lung cancers. These tumors usually have a high density of sst, but a great indi-
vidual variability in receptor density is observed. The clinical implications of these find-
ings in terms of diagnosis and therapy have been discussed elsewhere [2, 10]. Other
human tumors expressing sst include those ofthe nervous system (astrocytomas, neurob-
lastomas, meningiomas), malignant lymphomas, renal cell carcinomas and 50 percent of
breast tumors.
Human tumors may express different sst subtypes [11]. As shown, for instance, with
reverse transcriptase PCR andribonuclease protection assay, pituitary adenomas appear to
express all five sst subtypes, with particularly high levels of sst2 and sst5 [12, 13]. In situ
hybridization for sst subtype mRNAs showed that other human tumor types can also
express one or several ofthe sst subtypes [14, 15]. A frequently expressed subtype is sst2.
Figure 3 shows an example of a sst2 expressing meningioma. The fact that many tumors
express the sst2 subtype is important for sst in vivo imaging with octreotide-like ligands
because the human sst2 represents the subtype with the highest affinity for octreotide.
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Figure 3. sst2 subtype in a meningioma. A)
Hematoxylin-eosin stained section. Bar = 1
mm. B) Autoradiogram showing the lack of
sstl mRNA. C) Autoradiogram showing high
abundance of sst2 mRNA. D) Autoradiogram
showing total binding of'251-[Tyr3]-octreotide.
Non-specific binding was negligible.
Figure 4. sst in a peritumoral vein located in
fat tissue immediately adjacent to breast
cancer. A) Hematoxylin-eosin stained section.
Bar = 1 mm. The arrow shows an artery, the
arrowhead a vein. B) Autoradiogram showing
total binding of 125I-[Tyr3]-octreotide. The
vein, but not the artery, is strongly labeled. C)
Non-specific binding.
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In the next paragraphs, we would like to point towards selected tumor types that do
not yet belong to the well-known sst-expressing human tumor types, but were recently
identified as expressing sst.
Medulloblastomas
In an early study, we identified one medulloblastoma that had a very high sst density
[16]. We have recently confirmed these data in a joint study with the University of
Wurzburg [17] showing that 12/12 medulloblastomas expressed sst, usually in an
extremely high density comparable to that ofgastrinomas forinstance. The receptors were
preferentially of the sst2 subtype. This type of tumor, therefore, represents a new, poten-
tially important candidate for diagnosis with Octreoscan. More importantly, this tumor
type may be an adequate target for radiotherapy with radiolabeled somatostatin analogs,
due to its very high sst content.
Neuroblastomas
Neuroblastomas have also been shown in vitro to express sst in nearly 80 percent of
the cases. The particular interest in this tumor type is that the correlation ofsst expression
with survival was statistically significant [18]. The survival of those patients whose
tumors expressed sst was of longer duration than that of patients whose tumors did not.
This was an independent prognostic factor; sst were expressed more frequently in tumor
tissue from patients with lower stages ofdisease and in those with no evidence ofN-myc
amplification [18]. Survival analysis in this group of patients indicates that sst receptor
expression is a favorableprognostic factor, afinding that may have importantimplications
for the therapy in children with this malignancy [19].
Mesenchymal tumors
Not only can epithelial tumors frequently express sst, but also several types of mes-
enchymal tumors, as shown in a recent study [20]. Although only a limited number of
cases per tumor type could be evaluated in this study, it clearly indicates that mesenchy-
mal tumors, such as osteosarcomas, angiosarcomas, hemangiopericytomas, synovial sar-
comas, histiocytomas, and several muscle cell tumors, do express sst and should, therefore,
be included in the list oftumors to be considered as targets for diagnosis and therapy with
somatostatin analogs, in particular, hemangiopericytomas with their high sst density.
Prostate cancers
Prostate carcinomas represent a particular type of cancer since they usually do not
have sst which can be identified with 1251-[Tyr3]-octreotide. However, they express sst
identified with 1251-[Leu8, D-Trp22, Tyr25]-somatostatin-28, with a high affinity for
somatostatin-14 and somatostatin-28, but low affinity for octreotide [7]. The receptors are
located on tumor cells. In situ hybridization studies reveal a preferential expression of
sstl, very much compatible with the results ofpharmacological experiments. Moreover, a
sstl selective analog [21] is able to bind selectively and with high affinity to prostate can-
cer tissue, but not to sst2-, sst3- or sst5-expressing tumors [22]. Primary human prostate
cancers, therefore, express a different sst subtype than benign prostate tissue. It should be
emphasized that the above-mentioned study is based primarily on resectable primary
prostate cancers, belonging to GI and G2 (WHO) grading. It is not yet known whether
less differentiated, more aggressive prostate cancers also preferentially express sstl.
However, a recentjoint study with the University ofUppsala showed that hormone-insen-
sitive prostate cancers, metastatic to thebones, do express alow density ofoctreotide-sen-
sitive (sst2) receptors in this location, as shownby in vitro receptorautoradiographic stud-
ies [23]. About one-third of the metastatic lesions can be visualized in vivo with
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Octreoscan [23]. These data suggest that, in principle, human prostate cancers may be tar-
gets for somatostatin diagnosis and therapy. They appear to express different sst subtypes
in different tumor stages, implying that somatostatin analogs with different selectivities
for sst subtypes are required in each case. Although sstl selective analogs such as des
AA"5-[Tyr2, D-Trp8, IAmp9]somatostatin may theoretically be adequate to identify pri-
mary (GI and G2) prostate cancers [22], it should be remembered that those tumors are
resected surgically and usually do not need an alternative therapy. Conversely, advanced
metastatic prostate cancers appear to express sst2, but in such a low density that it would
notjustify the use of octreotide.
SOMATOSTATIN RECEPTORS IN PERITUMORAL VESSELS
Recently, the peritumoral vascular system of the host has emerged as a possible tar-
get ofsomatostatin action in tumordevelopment. In a series ofhuman colonic carcinomas,
ahigh density ofvascular ssthas been observed in the immediate vicinity ofall the tumors
(0 to 2 cm); as the distance from the carcinomas increases (5 to 10 cm), the density ofvas-
cular sst in the colon decreases considerably, suggesting alocal phenomenon related to the
presence of the tumor [24]. The presence of vascular sst seems to be independent of the
presence orabsence ofsst in the tumoritself. The sst was expressed by the veins and prob-
ably belongs to the sst2 subtype, since a high affinity for octreotide could be observed.
More recently, wehave investigated alarge numberofdifferent types ofhumanneoplasms
and found that the expression of sst in peritumoral veins is a general phenomenon,
although it appears highly variable [Denzler and Reubi, unpublished]. For instance, all
medullary thyroid carcinomas, colonic and gastric cancers express sst in peritumoral
veins, whereas this is rare in GEP tumors or ovarian cancers. A majority ofparathyroidea
adenomas, renal cell cancers, melanomas, sarcomas, breast cancers and prostate cancers
have sst in peritumoral veins [Denzler and Reubi, unpublished]. Figure 4 shows a peritu-
moral vein in the vicinity of a breast adenocarcinoma. In some tumors, such as
melanomas, the sst are not only expressed in peritumoral but also in intratumoral veins.
This may be the reason why it is possible to successfully visualize this type of tumor in
vivo with Octreoscan [25], although the melanoma itselfexpresses very few tumoral sst.
The function of somatostatin in the peritumoral vasculature, mediated by a high den-
sity of sst in the venous smooth muscle cells and possibly in the endothelium, can be
defined to some extent: in normal and pathological states, the vasoconstrictive effect of
somatostatin, in particular in the gut, is well-established [26]. Therefore, an increased sst
density may allow a strong and rapid vasoconstriction, possibly resulting in local hypox-
ia and necrosis of the tumor, or a more prolonged vasoconstriction, directed against
metastatic tumor dissemination. This mechanism may explain the occasional clinical
observation ofamarkeddecrease in tumor size during octreotide therapy in some patients.
Alternatively, somatostatin may regulate the extent of peritumoral inflammation, as has
been suggested for substance-P. Peritumoral veins, the main tumor-draining vessels, may
control processes such as the extravasation ofplasma, particularly of fibrin and of white
blood cells associated with inflammation, tumor stromal generation, blood flow in the
tumor, local thrombus formation and tumor growth and propagation. Finally, the high
expression of sst in peritumoral veins may be seen as a defense ofthe host against tumor
angiogenesis, as the latter can be inhibited by somatostatin analogs in the chick chorioal-
lantoic membrane system [27], possibly through sst similar to those identified in human
peritumoral vessels.
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Somatostatin may, therefore, act locally on tumorgrowth through two different mech-
anisms dependent on local sst expression: through direct action on tumor cells or through
action on peritumoral vessels, which may alter the hemodynamics ofthe tumor.
OUTLOOK
The clinical relevance of the above-mentioned high expression of sst in and around
tumors is two-fold: diagnostic and therapeutic. For the well-established indications, like
sst2 expressing neuroendocrine GEP tumors, an extensive discussion ofthe advantages of
the diagnostic use of Octreoscan or therapeutic and radiotherapeutic use of octreotide
analogs has been provided by several contributions to this conference. In this article, we
have introduced additional sst-expressing tumor types, i.e., medulloblastomas, heman-
giopericytomas and various mesenchymal tumors, which need to be evaluated in the
above-mentioned indications. We have also shown evidence of sst subtype expression by
human tumors. This may suggest development ofsubtype-specific ligands, i.e., sstl-selec-
tive analogs for primary prostate cancers; but the multiplicity of sst subtypes expressed
simultaneously in individual tumors may also suggest the development of stable, "pan-
somatostatin" analogs, i.e., analogs having a high affinity for all five sst subtypes. Such
compounds may improve the scintigraphic diagnosis of sst-expressing tumors, but they
may also have therapeutic effects differentfrom octreotide, which maybe worthwhile test-
ing in regard to the rather unsatisfactory antitumoral effect ofoctreotide in sst-expressing
non-endocrine tumors.
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